Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Interest Expenses for 4 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 11.69% to $16.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $68.1 million, a 5.41% decrease, with the full-year FY2025 number at $68.1 million, down 5.41% from a year prior.
  • Interest Expenses was $16.4 million for Q4 2025 at Phathom Pharmaceuticals, up from $16.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $18.6 million in Q4 2024 to a low of $2.8 million in Q1 2022.
  • A 4-year average of $13.1 million and a median of $14.6 million in 2023 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: skyrocketed 234.07% in 2023, then fell 12.85% in 2025.
  • Phathom Pharmaceuticals' Interest Expenses stood at $9.6 million in 2022, then surged by 35.69% to $13.0 million in 2023, then soared by 42.7% to $18.6 million in 2024, then fell by 11.69% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Interest Expenses are $16.4 million (Q4 2025), $16.1 million (Q3 2025), and $17.5 million (Q2 2025).